PuraMatrix® has demonstrated efficacy in multiple models for hemostasis (CE Mark approved, trade name PuraStat®), tissue regeneration, acute myocardial infarction, therapeutic protein and stem cell delivery, and CNS injury. PuraMatrix® can re-hydrate and provide mechanical support for disc height collapse in degenerated IVDs, anti-adhesion, polyp resection, and bone formation. PuraMatrix® has also been used to repair and restore visual function in the CNS after damage.
The prevention of myocardial injury post-myocardial infarction, both acute and chronic, is a critical clinical objective. Controlled delivery of drugs, biomaterials or cells directly to infarcted regions of the heart is an ideal approach to limit systemic toxicity and to improve the specificity and efficacy of a desired therapy. PuraMatrix® is an important stand-alone therapy for treatment of myocardial infarction via angiogenesis and tissue regeneration, as well as in conjunction with growth factors, biologics and cells.
Click here for peer-reviewed publications of PuraMatrix® in Cardiovascular clinical applications.